Market closedNon-fractional

TScan Therapeutics/TCRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About TScan Therapeutics

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Ticker

TCRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Waltham, United States

Employees

164

TCRX Metrics

BasicAdvanced
$302M
Market cap
-
P/E ratio
-$1.16
EPS
0.91
Beta
-
Dividend rate
$302M
0.91
5.233
5.171
66.382
74.624
-27.14%
-30.79%
-96.32%
32.098
2.22
2.22
-6.787
-14.47%
-61.41%
68.21%
-65.28%

What the Analysts think about TCRX

Analyst Ratings

Majority rating from 8 analysts.
Buy

TCRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-6,020.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$500K
-93.06%
Net income
-$30M
53.57%
Profit margin
-6,020.00%
2,111.45%

TCRX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 24.76%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.51
-$0.24
-$0.21
-$0.32
-
Expected
-$0.78
-$0.45
-$0.29
-$0.26
-$0.28
Surprise
-34.36%
-46.90%
-27.59%
24.76%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for TScan Therapeutics stock?

TScan Therapeutics (TCRX) has a market cap of $302M as of July 06, 2024.

What is the P/E ratio for TScan Therapeutics stock?

The price to earnings (P/E) ratio for TScan Therapeutics (TCRX) stock is 0 as of July 06, 2024.

Does TScan Therapeutics stock pay dividends?

No, TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next TScan Therapeutics dividend payment date?

TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders.

What is the beta indicator for TScan Therapeutics?

TScan Therapeutics (TCRX) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell TScan Therapeutics stock

Buy or sell TScan Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing